Private Placement Memorandum

When a company raises capital by private placement under Regulation D, it doesn’t file a public registration statement with the SEC. But silence is not an option. The company delivers a private placement memorandum (PPM) to prospective investors—a disclosure document that covers the business, risks, financial condition, use of proceeds, and investment terms. Despite the exemption from public registration, the PPM carries its own obligation: it must be truthful and must provide adequate information to allow sophisticated investors to make informed decisions.

The exempt offering context

Regulation D allows companies to raise capital without registering the securities with the SEC, provided they comply with specific conditions: limiting the number of investors (for Rule 506(b) offerings), or restricting offers to accredited investors (Rule 506(c)), and provided they file a Form D notice with the SEC. The exemption exists because registration is expensive and slow—perfect for a startup raising $5 million from a handful of investors, but wasteful if the company is issuing to 35 accredited investors who can fend for themselves.

But the exemption does not mean no disclosure. Issuers remain subject to Rule 10b-5, which bars fraudulent statements in connection with any sale of securities. The private placement memorandum is the mechanism through which most issuers discharge their disclosure obligation. It functions like a prospectus, except it’s private (not published or filed), and its audience is assumed to be financially sophisticated.

What goes into a PPM

A typical PPM includes:

• Executive Summary: A brief overview of the company, the offering, and key investment terms.
• Business Description: How the company makes money, its products or services, competitive position, and market.
• Risk Factors: Detailed discussion of business risks (competition, technology obsolescence, regulatory change), financial risks (liquidity, leverage), and investment-specific risks (illiquidity of the securities being offered, lack of secondary market).
• Management and Capitalization: Bios of the CEO, CFO, and key officers; ownership structure; and how much capital the company has raised before.
• Use of Proceeds: Where the investment capital will go—R&D, sales, working capital, debt repayment.
• Financial Information: Audited or reviewed financial statements (if available), or at minimum unaudited financials and a management discussion of the company’s financial position.
• Subscription Agreement: The legal terms—price per share, dilution rights, anti-dilution provisions, liquidation preferences, and information rights.
• Legends and Restrictions: Disclosure that the securities are restricted (not easily resold), illiquid, and subject to holding periods.

The level of detail varies. A Series A venture deal might include a detailed technical description of the product and market analysis. A private debt offering might focus heavily on the issuer’s cash flow and debt service capacity. The issuer and its counsel tailor the document to the investment type and investor sophistication.

Disclosure tailored to sophistication

Unlike public prospectuses, which assume a retail investor base of varying financial literacy, the PPM assumes the recipients are sophisticated. They may be venture capital funds, angels with business experience, or institutional investors. This allows the PPM to include more technical or industry-specific information without explanation—a biotech PPM can discuss Phase 2 trials and FDA pathways without defining each term.

But assumption of sophistication does not excuse the issuer from disclosure. A rule of thumb: if a sophisticated investor would want to know something in deciding whether to buy, it belongs in the PPM. A company hiding a pending lawsuit, a major customer loss, or technical failure in the product in hopes that “only sophisticated investors” will be reading understands the rule backwards. Courts and the SEC will find the omission material and actionable under Rule 10b-5 regardless of investor sophistication.

The no-verification clause and materiality

Most PPMs contain a prominent disclaimer: “This memorandum has not been filed with or reviewed by the SEC. We have not verified the facts stated herein, and no assurance is given that they are accurate.” That language warns investors they are not relying on an SEC seal of approval. But the disclaimer does not shield the issuer from liability. If facts in the PPM are false, the issuer is liable under Rule 10b-5 regardless of the disclaimer. The clause simply clarifies that the SEC has not vouched for the document; it does not authorize misstatement.

Materiality is the threshold. A minor factual error—off-by-one-digit hiring count, or a product feature described slightly inaccurately—may not be material. But concealing a litigation risk, overstating gross margins, or omitting a competing product launch is material. The question is whether a reasonable investor would consider the fact important in the investment decision.

Limits on resale and legend restrictions

PPM offerings almost always restrict resale. The securities are not registered, so they cannot be sold publicly without registration or an exemption. The PPM includes a “legend” (literal language on the stock certificate) and subscription agreement language stating that the securities may not be sold for at least one year (often longer) without SEC registration or another exemption. This lock-in protects investors (it signals real skin-in-the-game by early investors and reduces dilution) but creates illiquidity risk.

The PPM must disclose this plainly. An investor reading that the securities are restricted for at least one year should understand they cannot exit quickly. The absence of a secondary market for the securities is a major risk factor, and material issuers highlight it prominently.

Antifraud liability and evolution

The most important point: a PPM offer or sale to even one investor creates liability under Rule 10b-5 if the PPM contains a material misstatement or omission and the investor relied on it. This applies whether the offering is Rule 506, Rule 505, or Regulation A. The issuer cannot hide behind the “private” label.

Over time, as Regulation D offerings have grown (now accounting for a significant share of early-stage capital), the SEC has scrutinized PPM disclosure more closely. In enforcement actions, the agency has challenged omissions of risk factors (medical product PPM that didn’t disclose FDA rejection letters), misstatements of revenue (PPM that claimed higher sales than actual), and conflicts of interest (PPM that didn’t disclose that management had competing businesses). Issuers who rely on the exemption must still provide honest, complete disclosure.

See also